𝔖 Bobbio Scriptorium

✦ LIBER ✦

Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial

Book ID: 118588520
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 84 KB
Volume: 32
Category: Article
ISSN: 1558-3597
DOI: 10.1016/s0735-1097(98)00474-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized, placebo-controlled study of

Randomized, placebo-controlled study of Lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: Rationale and design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) study

✍ David J. Moliterno; Robert A. Harrington; Robert M. Califf; Hans J. Rapold; Eric 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 583 KB

The Efficacy and Safety of Prasugrel Wit

The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention: A TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38) Analysis

✍ Michelle O'Donoghue; Elliott M. Antman; Eugene Braunwald; Sabina A. Murphy; P. G 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 480 KB